A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 1,115,466 shares of VERV stock, worth $6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,115,466
Previous 2,592,198 56.97%
Holding current value
$6 Million
Previous $34.4 Million 84.19%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$4.76 - $12.79 $7.03 Million - $18.9 Million
-1,476,732 Reduced 56.97%
1,115,466 $5.44 Million
Q1 2024

Apr 19, 2024

BUY
$10.81 - $17.96 $2.1 Million - $3.49 Million
194,594 Added 8.12%
2,592,198 $34.4 Million
Q4 2023

Jan 30, 2024

BUY
$8.84 - $18.7 $2.21 Million - $4.68 Million
250,361 Added 11.66%
2,397,604 $33.4 Million
Q3 2023

Oct 30, 2023

SELL
$11.42 - $20.82 $440,971 - $803,943
-38,614 Reduced 1.77%
2,147,243 $28.5 Million
Q2 2023

Jul 31, 2023

BUY
$13.34 - $19.9 $7.84 Million - $11.7 Million
587,863 Added 36.79%
2,185,857 $41 Million
Q1 2023

Apr 27, 2023

BUY
$14.3 - $24.01 $5.28 Million - $8.87 Million
369,547 Added 30.08%
1,597,994 $23 Million
Q4 2022

Jan 30, 2023

BUY
$17.85 - $40.7 $8.08 Million - $18.4 Million
452,750 Added 58.37%
1,228,447 $23.8 Million
Q3 2022

Oct 21, 2022

BUY
$15.63 - $41.49 $10.3 Million - $27.4 Million
660,465 Added 573.16%
775,697 $26.6 Million
Q2 2022

Jul 26, 2022

BUY
$11.14 - $23.17 $1.28 Million - $2.67 Million
115,232 New
115,232 $1.76 Million
Q1 2022

Apr 27, 2022

SELL
$20.92 - $39.36 $1.48 Million - $2.79 Million
-70,950 Closed
0 $0
Q4 2021

Feb 02, 2022

SELL
$31.94 - $54.82 $238,623 - $409,560
-7,471 Reduced 9.53%
70,950 $2.62 Million
Q3 2021

Oct 25, 2021

BUY
$46.0 - $73.99 $3.61 Million - $5.8 Million
78,421 New
78,421 $3.69 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $322M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.